Ventyx Biosciences reported Phase II results showing its oral NLRP3 inhibitor VTX‑3232 produced rapid reductions in inflammatory biomarkers and surrogate measures of cardiovascular risk, including a near 78% drop in high‑sensitivity C‑reactive protein (hsCRP) within 12 weeks for monotherapy patients. The company studied 175 patients with obesity and cardiovascular risk factors and reported statistically significant decreases in IL‑6, Lp(a), fibrinogen and liver‑inflammation markers. Safety and tolerability met the study’s primary goals, and Ventyx said the profile supports further development in cardiometabolic indications. Investors responded strongly, lifting Ventyx shares and drawing attention to NLRP3 as a therapeutic axis for atherosclerosis and related diseases. Ventyx emphasized potential regulatory and partnering conversations to advance larger cardiovascular outcome studies.